Radiology:三维MR弹性成像,做到慢性肝炎患者的“一站式”检查!

2021-08-23 shaosai MedSci原创

现阶段,慢性乙型肝炎(CHB)和丙型肝炎(CHC)仍然是全世界范围内的一个重要健康问题。在对这类患者进行诊治时,肝脏纤维化(LF)的严重程度是一项十分重要的评估手段。

现阶段慢性乙型肝炎(CHB)和丙型肝炎(CHC)仍然是世界范围内的一个要健康问题。在对这类患者进行诊治时,肝脏纤维化(LF)严重程度是一项十分重要的评估手段多项研究证实MR弹性成像是现阶段评估LF准确的成像方法之一。

尽管弹性成像技术在对LF进行分期时具有优越性,但研究发现,基于二维MR弹性成像的肝脏硬度(即剪切硬度[SS])也炎症(如非酒精性脂肪性肝炎)或门静脉高压(PH)的影响。相比之下,多参数三维(3D)MR弹性成像允许组织的基本粘弹性建模,将复杂的剪切模量划分为弹性成分(如存储模量)和粘性成分(如损失模量和阻尼比[DR])。然而据我们所知尚未有研究探讨三维MR弹性成像在CHB或CHC中使用。

近日,发表在Radiology杂志的一项研究评估多参数三维MR弹性成像检测早期坏死性炎症、区分坏死性炎症和纤维化以及衡量CHB和CHC门静脉高压的严重程度方面的价值为临床慢性肝炎患者准确诊治提供了影像学保障

从2015年1月到2019年9月,本研究从一个机构前瞻性地招募了CHB或CHC患者,并将其分为两组:有肝脏活检且无PH证据的患者(第1组)和有PH肝静脉压力梯度(HVPG)测量的患者(第2组)。从附近的社区招募了健康志愿者作为第3组。使用60赫兹的三维MR弹性成像技术对多个粘弹性参数(剪切刚度[SS]、储能模量、损耗模量和阻尼比[DR])进行测定,并使用多变量逻辑或线性回归分析来评估机械参数与组织学评分和HVPG的关联。

1组共有155名参与者(中位年龄,41岁[四分位数范围,32-48岁];85名女性),第2组有85名参与者(中位年龄,57岁[四分位数范围,43-61岁];51名女性),第3组有60名健康志愿者(中位年龄,49岁[四分位数范围,27-64岁];38名男性)。有坏死性炎症的参与者(DR,0.13 ± 0.03)与没有坏死性炎症的参与者(肝纤维化F0期)(DR,0.10 ± 0.02;P < .001)相比,肝脏DR更高在验证数据集中,肝脏DR和SS在诊断坏死性炎症受试工作特征曲线下的面积[AUC],0.88[95% CI: 0.79, 0.96])和中度至重度活动评分(AUC,0.88[95% CI: 0.81, 0.95])方面表现良好肝脏DR(回归系数[β] = -30.3 [95% CI: -58.0, -2.5]; P = .03)和脾脏SS(β = 2.3 [95% CI: 1.7, 2.9]; P < .001)与HVPG独立相关

 

 健康对照组和慢性乙型或丙型肝炎患者(用虚线勾勒的肝脏)的三维MR弹性成像图像。(A)对照组的肝脏剪切刚度(SS)图。(B) F0至F4期肝纤维化(LF)患者的肝脏SS图。(C) 对照组的阻尼比(DR)图。(D) F0到F4阶段的LF患者的DR图。

本研究表明,先进的三维(3D)MR弹性成像是一种简单、快速有效的用于慢性乙型或丙型肝炎患者诊治评估的影像学手段为临床提供了全面检测早期坏死性炎症、区分坏死性炎症和纤维化并一次性测量门静脉高压的严重程度的有效工具使得该类患者的个性化评估和医疗护理成为可能

原文出处

Yu Shi,Ya-Fei Qi,Gong-Yu Lan,et al.Three-dimensional MR Elastography Depicts Liver Inflammation, Fibrosis, and Portal Hypertension in Chronic Hepatitis B or C.DOI:10.1148/radiol.2021202804

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2079860, encodeId=c13920e986041, content=<a href='/topic/show?id=c8bc1225620' target=_blank style='color:#2F92EE;'>#MR弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12256, encryptionId=c8bc1225620, topicName=MR弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu Dec 09 08:50:20 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951828, encodeId=cca7195182830, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Jun 13 19:50:20 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645989, encodeId=b6b216459890e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Sat Feb 19 07:50:20 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807918, encodeId=d7a5180e91825, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Dec 19 23:50:20 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674902, encodeId=c53416e49029c, content=<a href='/topic/show?id=9c6b5362561' target=_blank style='color:#2F92EE;'>#慢性肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53625, encryptionId=9c6b5362561, topicName=慢性肝炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e1127134834, createdName=redcrab, createdTime=Thu Jun 16 12:50:20 CST 2022, time=2022-06-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2079860, encodeId=c13920e986041, content=<a href='/topic/show?id=c8bc1225620' target=_blank style='color:#2F92EE;'>#MR弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12256, encryptionId=c8bc1225620, topicName=MR弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu Dec 09 08:50:20 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951828, encodeId=cca7195182830, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Jun 13 19:50:20 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645989, encodeId=b6b216459890e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Sat Feb 19 07:50:20 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807918, encodeId=d7a5180e91825, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Dec 19 23:50:20 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674902, encodeId=c53416e49029c, content=<a href='/topic/show?id=9c6b5362561' target=_blank style='color:#2F92EE;'>#慢性肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53625, encryptionId=9c6b5362561, topicName=慢性肝炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e1127134834, createdName=redcrab, createdTime=Thu Jun 16 12:50:20 CST 2022, time=2022-06-16, status=1, ipAttribution=)]
    2022-06-13 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=2079860, encodeId=c13920e986041, content=<a href='/topic/show?id=c8bc1225620' target=_blank style='color:#2F92EE;'>#MR弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12256, encryptionId=c8bc1225620, topicName=MR弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu Dec 09 08:50:20 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951828, encodeId=cca7195182830, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Jun 13 19:50:20 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645989, encodeId=b6b216459890e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Sat Feb 19 07:50:20 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807918, encodeId=d7a5180e91825, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Dec 19 23:50:20 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674902, encodeId=c53416e49029c, content=<a href='/topic/show?id=9c6b5362561' target=_blank style='color:#2F92EE;'>#慢性肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53625, encryptionId=9c6b5362561, topicName=慢性肝炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e1127134834, createdName=redcrab, createdTime=Thu Jun 16 12:50:20 CST 2022, time=2022-06-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2079860, encodeId=c13920e986041, content=<a href='/topic/show?id=c8bc1225620' target=_blank style='color:#2F92EE;'>#MR弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12256, encryptionId=c8bc1225620, topicName=MR弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu Dec 09 08:50:20 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951828, encodeId=cca7195182830, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Jun 13 19:50:20 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645989, encodeId=b6b216459890e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Sat Feb 19 07:50:20 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807918, encodeId=d7a5180e91825, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Dec 19 23:50:20 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674902, encodeId=c53416e49029c, content=<a href='/topic/show?id=9c6b5362561' target=_blank style='color:#2F92EE;'>#慢性肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53625, encryptionId=9c6b5362561, topicName=慢性肝炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e1127134834, createdName=redcrab, createdTime=Thu Jun 16 12:50:20 CST 2022, time=2022-06-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2079860, encodeId=c13920e986041, content=<a href='/topic/show?id=c8bc1225620' target=_blank style='color:#2F92EE;'>#MR弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12256, encryptionId=c8bc1225620, topicName=MR弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Thu Dec 09 08:50:20 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951828, encodeId=cca7195182830, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Jun 13 19:50:20 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645989, encodeId=b6b216459890e, content=<a href='/topic/show?id=663550088ef' target=_blank style='color:#2F92EE;'>#弹性成像#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50088, encryptionId=663550088ef, topicName=弹性成像)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb23278887, createdName=tamgche, createdTime=Sat Feb 19 07:50:20 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807918, encodeId=d7a5180e91825, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Dec 19 23:50:20 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674902, encodeId=c53416e49029c, content=<a href='/topic/show?id=9c6b5362561' target=_blank style='color:#2F92EE;'>#慢性肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53625, encryptionId=9c6b5362561, topicName=慢性肝炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e1127134834, createdName=redcrab, createdTime=Thu Jun 16 12:50:20 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

相关资讯

上海试点免费为慢性肝炎患者家庭提供签约管理服务

记者在全国爱肝日到来之际从上海市疾控中心获悉:上海在全国率先开展慢性肝炎患者签约管理工作,已有27个试点社区免费为慢性肝炎患者家庭提供签约管理服务。

JGH OPEN:丙氨酸转氨酶长期> 1000 IU / L的后果

丙氨酸氨基转移酶(ALT)的明显升高是由基础疾病引起的,这些病理改变包括肝缺血,药物/毒素,病毒性肝炎,以及罕见的自身免疫性肝炎。

综述:慢性丙肝患者的规范化治疗

       我国是一个乙型肝炎(简称乙肝)大国,临床医师及公众对乙肝的认知度、警觉度均较高,而丙型肝炎(简称丙肝)却往往被忽视,以致其早期发现率和诊断率均较低。事实上,丙肝在世界范围呈广泛流行,是欧美及日本等国家终末期肝病的最主要原因。在我国一般人群中,抗-HCV阳性率也有0.43%。丙肝病毒(HCV)感染的慢性化率(50%~85%)远

Liver Int:直接抗病毒治疗对合并慢性肝炎或肝硬化的2型糖尿病的长期血糖控制的影响

直接抗病毒治疗对合并慢性肝炎或肝硬化的2型糖尿病的长期血糖控制的影响